MHRA raid: 12,000 unlicensed peptide doses seized in UK

Peptides and GLP-1 medicines are active ingredients that mimic the body's natural satiety hormones, which is why they are seen as highly effective but fiercely contested weight-loss injections. Peptides themselves are short protein building blocks that act in the body like hormone-like messengers. The UK's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), seized roughly 12,000 doses of such unlicensed weight-loss injections on the night of May 28, 2026, on a country estate in Northamptonshire^[1], including the experimental substance retatrutide and tirzepatide^[2]. According to the agency, it is the largest single seizure of its kind in the MHRA's history. Two men, both 29, were arrested under the Human Medicines Regulations 2012 (the UK medicines regulation)^[1]. The raid is the latest in a series of UK operations targeting the black market for GLP-1 and peptide products - injections based on the GLP-1 hormone (the same mechanism used by Ozempic, Wegovy and Mounjaro). I document this series here.

Key takeaways

• Around 12,000 doses of unlicensed peptide weight-loss medicines were seized on May 28, 2026, on a country estate near Northampton, the largest such seizure in MHRA history^[1].
• Recovered substances included retatrutide (still in clinical trials, no legal supply anywhere), tirzepatide (prescription-only), and other peptide products^[2].
• Two men aged 29 were arrested under the Human Medicines Regulations 2012; the investigation is ongoing^[1].
• In October 2025 the MHRA had already dismantled the UK's first illicit weight-loss injection production facility, also in Northampton^[3].
• In February 2026, follow-up raids in Lincolnshire and Nottinghamshire recovered roughly 2,000 more doses^[3].

What exactly happened during the MHRA raid on May 28, 2026?

The MHRA's Criminal Enforcement Unit (CEU) - its law-enforcement branch - carried out the raid late on May 28, 2026, with Northamptonshire Police support, and uncovered a professionally built production, filling and packaging facility for peptide injection pens, together with substantial packaging materials and pharmaceutical substances used in illicit manufacture^[1].

Andy Morling, head of the MHRA Criminal Enforcement Unit, said that dismantling the production site had not only disrupted an organised criminal group but also prevented significant public harm^[2]. The agency called it a "large-scale facility to manufacture, assemble and distribute", a description that points to logistics rather than a lone operator.

Which substances were seized?

From the country-estate raid on May 28, 2026, the MHRA confirmed three substance categories among the seized material: retatrutide, tirzepatide, and other unlicensed peptide products^[1]. Retatrutide is a triple agonist - meaning a substance that simultaneously signals the body through three different pathways that the stomach is full and energy needs to be burned. The substance is still in clinical trials worldwide with no legal supply anywhere. Tirzepatide is prescription-only and sold under the brand name Mounjaro through regulated pharmacy channels.

What the seized pens actually contained remains unknown. In comparable cases investigated by Australian authorities, lab analyses of fake retatrutide vials showed that some contained no active ingredient at all while others held contaminated or underdosed substances, causing severe liver injury in users, a topic I have documented in my piece on retatrutide counterfeits in Australia.

What is the legal situation in the UK?

In the UK, manufacturing, possessing and selling unlicensed medicines is a criminal offence under the Human Medicines Regulations 2012 (the UK medicines regulation). The two 29-year-old men were arrested under exactly this provision on May 28, 2026. They now face potential heavy fines and prison sentences^[1].

At the EU level, the parallel warning from EMA and HMA in spring 2026 shows that authorities now treat illegal trade in GLP-1 and peptide products as a cross-border problem. My overview of the EMA/HMA warning on illegal GLP-1 products puts the UK and EU crackdown in context.

Is this case connected to earlier UK raids?

Yes, the MHRA explicitly describes the May 28, 2026 raid as part of an ongoing series of investigations into the illegal supply of weight-loss injections in the UK, a series that has been running since October 2025 and now spans multiple regions plus an international enforcement network^[1].

The series began in October 2025, when the agency dismantled the UK's first illicit weight-loss injection production facility, also in a Northampton warehouse^[3]. February 2026 brought follow-up raids in Lincolnshire and Nottinghamshire that recovered roughly 2,000 doses, plus further actions in subsequent months. The agency had previously called that earlier seizure the "largest single seizure of trafficked weight-loss medicines ever recorded globally", a record now exceeded by the May 2026 operation^[3]. In parallel, the international Operation Pangea XIX - a global police operation against illegal medicines - saw the MHRA and UK Border Force seize more than 2 million doses of illegal medicines worth GBP 4.6 million between March 10 and 23, 2026 alone^[4].

What does this mean for buyers in the UK and EU?

The May 28, 2026 findings show that the UK peptide black market has long since outgrown small online shops; it now runs on professional supply chains with production, packaging and distribution know-how, raising both the legal and the health risks for anyone buying outside licensed pharmacies.

Beyond the legal risk, product quality on the black market is not assured: in recent lab testing, roughly one in three products sold as "research peptides" was contaminated (that is, one in three substances officially declared as research chemicals only and never intended for human use), as my analysis of peptide lab tests 2026 documents. For buyers this means no traceable cold chain (no continuously chilled supply chain from production to buyer), no provenance, no batch certificate (meaning no document confirming that the specific production batch met quality standards), and, in the worst case, a substance whose contents no one has checked.

Note: This article is for informational purposes only and does not constitute medical advice. It is not a recommendation to buy or dose peptides or GLP-1 medicines.